Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

2008778 citationsJournal Articlebronze Open Access

Authors

Salim Yusuf · Population Health Research Institute

Hans‐Christoph Diener · University of Duisburg-Essen

Ralph L. Sacco · University of Miami

Otto W. Witte · Boehringer Ingelheim (United States)

Stephanie Ôunpuu · Boehringer Ingelheim (Canada)

William A Lawton

Yuko Palesch · Medical University of South Carolina

Abstract

Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)

Topics & Keywords

Renin-Angiotensin System Studies Blood Pressure and Hypertension Studies Atrial Fibrillation Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 359, Issue 12, pp. 1225-1237

DOI: 10.1056/nejmoa0804593

Field-Weighted Citation Impact: 52.77